Drug Profile
VIS 705
Alternative Names: VIS-705Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Visterra
- Class Antibacterials; Antibodies; Drug conjugates; Peptides
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Parenteral)
- 23 Aug 2021 Preclinical development is still ongoing for Bacterial infections in USA (Visterra pipeline, August 2021)
- 23 Aug 2021 VIS 705 is available for licensing as of 23 Aug 2021. https://www.visterrainc.com/#contactus